Cara Historical Cash Flow
| CARA Stock | USD 0.31 0.01 3.33% |
Analysis of Cara Therapeutic cash flow over time is an excellent tool to project Cara Therapeutic future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 10.7 M or Begin Period Cash Flow of 67.4 M as it is a great indicator of Cara Therapeutic ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cara Therapeutic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cara Therapeutic is a good buy for the upcoming year.
Cara |
About Cara Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cara balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cara's non-liquid assets can be easily converted into cash.
Cara Therapeutic Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Cara Therapeutic financial statement analysis. It represents the amount of money remaining after all of Cara Therapeutic operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most accounts from Cara Therapeutic's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.At present, Cara Therapeutic's Change In Working Capital is projected to decrease significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 67.4 M, whereas Change In Cash is projected to grow to (9.9 M).
Cara Therapeutic cash flow statement Correlations
Click cells to compare fundamentals
Cara Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cara Therapeutic cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.9M | 13.4M | (18.2M) | 50.3M | (10.5M) | (9.9M) | |
| Stock Based Compensation | 12.6M | 14.8M | 20.8M | 17.7M | 13.7M | 8.6M | |
| Free Cash Flow | (109.2M) | (5.8M) | (60.1M) | (78.8M) | (94.5M) | (89.7M) | |
| Change In Working Capital | (18.8M) | (29.6M) | 5.3M | (12.9M) | 10.2M | 10.7M | |
| Begin Period Cash Flow | 15.9M | 18.7M | 32.1M | 13.9M | 64.1M | 67.4M | |
| Total Cashflows From Investing Activities | (30.5M) | (20.3M) | (4.8M) | 128.7M | 148.0M | 155.4M | |
| Other Cashflows From Financing Activities | 142.6M | 691K | 1.6M | 311K | 37.0M | 41.8M | |
| Depreciation | 370K | 198K | 209K | 248K | 259K | 498.1K | |
| Other Non Cash Items | 4.6M | 806K | 1.3M | 1.7M | 2.3M | 1.2M | |
| Capital Expenditures | 18K | 349K | 39K | 43K | 2.4M | 2.5M | |
| Total Cash From Operating Activities | (109.2M) | (5.5M) | (60.1M) | (78.7M) | (92.1M) | (87.5M) | |
| Net Income | (106.4M) | 8.4M | (88.4M) | (85.5M) | (118.5M) | (112.6M) | |
| Total Cash From Financing Activities | 142.6M | 39.1M | 46.6M | 311K | 38.2M | 52.4M | |
| End Period Cash Flow | 18.7M | 32.1M | 13.9M | 64.1M | 53.7M | 56.4M | |
| Change To Liabilities | 6.0M | (2.8M) | (1.0M) | 5.7M | 6.5M | 6.9M | |
| Change To Account Receivables | (197K) | (277K) | 1.0M | (3.3M) | 436K | 457.8K | |
| Sale Purchase Of Stock | 142.6M | 691K | 1.6M | 311K | 279.9K | 265.9K | |
| Change To Inventory | (2.6M) | 197K | 277K | 201K | (438K) | (459.9K) | |
| Investments | (32.5M) | (47.0M) | (25.3M) | 124.8M | 118.1M | 124.0M | |
| Cash And Cash Equivalents Changes | 2.9M | 13.4M | (18.2M) | 50.3M | 57.8M | 60.7M | |
| Cash Flows Other Operating | (20.2M) | (26.7M) | 10.0M | (14.1M) | (12.7M) | (12.0M) | |
| Change To Operating Activities | (4.9M) | (4.3M) | 8.0M | (15.5M) | (14.0M) | (13.3M) | |
| Other Cashflows From Investing Activities | 2M | 27.0M | 20.6M | 4M | 4.6M | 4.8M | |
| Change To Netincome | 12.6M | 14.8M | 20.7M | 17.7M | 20.4M | 10.7M | |
| Change Receivables | (45K) | 414K | 102K | (3.3M) | (3.0M) | (2.8M) | |
| Issuance Of Capital Stock | 136.5M | 38.4M | 45.0M | 0.0 | 1.1M | 1.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.